ライフサイエンスコーパス: sarcoidosis

1 -> uncomplicated sarcoidosis --> complicated sarcoidosis).

2 and nervous system involvement (complicated sarcoidosis).

3 Orbital imaging could not diagnose sarcoidosis.

4 coded with the dual diagnoses of uveitis and sarcoidosis.

5 entiated uveitis who underwent screening for sarcoidosis.

6 s regulate Th1/Th17 mediated inflammation in sarcoidosis.

7 ual tests correctly identified patients with sarcoidosis.

8 cs to reveal novel mechanisms operational in sarcoidosis.

9 ated sarcoidosis, and finally to complicated sarcoidosis.

10 MC gene expression is useful in diagnosis of sarcoidosis.

11 atous disease with clinical implications for sarcoidosis.

12 rdial inflammation in patients with systemic sarcoidosis.

13 iseases such as leukemia, kidney disease and sarcoidosis.

14 ardial involvement in patients with systemic sarcoidosis.

15 ts are effective but suspensive in cutaneous sarcoidosis.

16 d patients with uncomplicated or complicated sarcoidosis.

17 iabetes mellitus, syphilis, tuberculosis and sarcoidosis.

18 for patients with known or suspected cardiac sarcoidosis.

19 outcome of CA of VT in patients with cardiac sarcoidosis.

20 ferred to MRI for known or suspected cardiac sarcoidosis.

21 eceptors on blood monocytes in patients with sarcoidosis.

22 cells are a prominent source of IFN-gamma in sarcoidosis.

23 ed as a useful tool for diagnosis of cardiac sarcoidosis.

24 thways may prove to be a novel treatment for sarcoidosis.

25 nd in lung lavage, invoking Th17 immunity in sarcoidosis.

26 of patients with known or suspected cardiac sarcoidosis.

27 that is associated with a good prognosis in sarcoidosis.

28 rohn's disease, Wegener's granulomatosis, or sarcoidosis.

29 rchitecture or its broader phenotype, non-LS sarcoidosis.

30 nt ACE levels in 148 patients diagnosed with sarcoidosis.

31 monocyte and macrophage hyper-activation in sarcoidosis.

32 vement occurs in perhaps 5% of patients with sarcoidosis.

33 ted in the peripheral blood of patients with sarcoidosis.

34 ower in the lacrimal gland for patients with sarcoidosis.

35 obtained from 12 historical individuals with sarcoidosis.

36 d to steroid use and those likely related to sarcoidosis.

37 he orbital adipose tissue from patients with sarcoidosis.

38 vide diagnostic information in patients with sarcoidosis.

39 signaling pathway in the genetic etiology of sarcoidosis.

40 ermatologists and nondermatologists treating sarcoidosis.

41 s and in peripheral blood from patients with sarcoidosis.

42 hest imaging changes suggesting either TB or sarcoidosis.

43 ic tests in patients with suspected or known sarcoidosis.

44 to development and progression of pulmonary sarcoidosis.

45 cularly heart failure (HF), in patients with sarcoidosis.

46 jects from the background population without sarcoidosis.

47 ding idiopathic pulmonary fibrosis (IPF) and sarcoidosis.

48 ACE and lymphopenia had evidence of systemic sarcoidosis.

49 40 subjects, of whom 18 (45.0%) had systemic sarcoidosis.

50 have poor sensitivity for diagnosing cardiac sarcoidosis.

51 t disease and granulomatous diseases such as sarcoidosis.

52 d hypoxia inducible factor (HIF) pathways in sarcoidosis.

53 gnoses of uveitis and presumed/biopsy-proven sarcoidosis.

54 reening alone would still miss many cases of sarcoidosis.

55 tients with suspected or established cardiac sarcoidosis.

56 in chronic obstructive pulmonary disease or sarcoidosis.

57 43 subjects, of whom 29 (67.4%) had systemic sarcoidosis.

58 llomic profiles compared with civilians with sarcoidosis.

59 ion, and management of patients with cardiac sarcoidosis.

60 veteran and civilian patients with confirmed sarcoidosis.

61 different molecular phenotypic responses of sarcoidosis.

62 udden cardiac death in patients with cardiac sarcoidosis.

63 Of the 12,042 patients diagnosed with sarcoidosis, 11,834 patients were matched with 47,336 su

64 patients age >=18 years with newly diagnosed sarcoidosis (1996 to 2016) were identified through Danis

65 sy-proven extracardiac diagnosis of systemic sarcoidosis (21 men; median age, 45 years; interquartile

66 iagnosis was made in 36.1% of patients, with sarcoidosis (22.6%) and multiple sclerosis (4.6%) the mo

67 Of 15 130 subjects with sarcoidosis, 3364 (22.2%) were evaluated in an eye clini

68 inflammation (NSOI) (22 scans, 14 patients), sarcoidosis (4 scans, 3 patients), IgG4-related ophthalm

69 al study evaluating the use of the Cutaneous Sarcoidosis Activity and Morphology Instrument (CSAMI) a

70 tivity and Morphology Instrument (CSAMI) and Sarcoidosis Activity and Severity Index (SASI) to assess

71 d disease-related factors.Methods: Using the Sarcoidosis Advanced Registry for Cures database, we ana

72 (uncomplicated sarcoidosis), however, 20% of sarcoidosis-affected individuals experience progressive

73 ystem disorder of unknown cause, and cardiac sarcoidosis affects at least 25% of patients and account

74 kinase responsible for activation of p38 in sarcoidosis alveolar macrophages (AMs) and PBMCs.

75 re reliable and valid in assessing cutaneous sarcoidosis among our diverse group of specialists.

76 tified that sustained p38 phosphorylation in sarcoidosis AMs and PBMCs is associated with active MAPK

77 Additionally, we found that sarcoidosis AMs exhibit a higher expression of IRAK1, IR

78 Surprisingly, ex vivo treatment of sarcoidosis AMs or PBMCs with IRAK1/4 inhibitor led to a

79 ation of BALF exosomes from 15 patients with sarcoidosis and 5 healthy control subjects and verified

80 o >100 cells per microliter in patients with sarcoidosis and a fivefold depletion of the slan-positiv

81 in many diseases including schistosomiasis, sarcoidosis and arthritis.

82 rocalcification and in patients with cardiac sarcoidosis and cardiac amyloidosis will also be describ

83 Although sarcoidosis and celiac disease are both chronic immunolo

84 Associations of sarcoidosis and celiac disease are rare but do occur.

85 Patients with sarcoidosis and drug toxicity-related ILD were excluded.

86 e (BAL) and serum samples from patients with sarcoidosis and healthy and diseased control subjects to

87 differentially expressed (DE) genes between sarcoidosis and healthy control monocytes.

88 in patients with known or suspected cardiac sarcoidosis and identified topics for future research.

89 cohort study of patients with biopsy-proven sarcoidosis and known or suspected cardiac sarcoidosis t

90 an age, 45.7 years) with proven extracardiac sarcoidosis and possible CS who were investigated with f

91 etic resonance in patients with extracardiac sarcoidosis and preserved left ventricular ejection frac

92 ch to the management of pulmonary disease in sarcoidosis and provide details about how and when to us

93 Included patients had histologically proven sarcoidosis and received anti-TNF between January 2004 a

94 University Medical Center with biopsy-proven sarcoidosis and SAPH confirmed by right heart catheteriz

95 Of the 46 patients with sarcoidosis and skin involvement who were treated with a

96 rditis, eosinophilic myocarditis, or cardiac sarcoidosis and those <15 years of age were excluded fro

97 avage fluid (BALF) exosomes in patients with sarcoidosis and to find candidates for disease biomarker

98 eover, the results showed that veterans with sarcoidosis and veterans with COPD were similar to each

99 Patients with cardiac sarcoidosis and VT exhibit ventricular substrate charact

100 In patients with cardiac sarcoidosis and VT, CA is effective in achieving long-te

101 ogically confirmed IgG4-RD, 11 patients with sarcoidosis, and 30 healthy subjects were included for 1

102 rall, 70% of patients had stage IV pulmonary sarcoidosis, and 77% had functional class III/IV symptom

103 hopenia were strongly suggestive of systemic sarcoidosis, and biopsy of skin lesions may detect patie

104 recognition of cardiac amyloidosis, cardiac sarcoidosis, and cardiac hemochromatosis and imaging tec

105 are available: cardiac amyloidosis, cardiac sarcoidosis, and cardiac hemochromatosis.

106 erved from healthy control, to uncomplicated sarcoidosis, and finally to complicated sarcoidosis.

107 2 treatment-related events (cardiac failure, sarcoidosis, and foot fracture, all in bevacizumab-treat

108 nulomatous diseases, such as tuberculosis or sarcoidosis, and is decisive for disease pathogenesis.

109 toimmune diseases (e.g., multiple sclerosis, sarcoidosis, and juvenile rheumatoid arthritis).

110 tious granulomatous lung diseases, including sarcoidosis; and selected respiratory infections.

111 iagnosis, particularly between silicosis and sarcoidosis, are highlighted, as is the importance of ob

112 ects and higher percentages in patients with sarcoidosis as well as at high percentages among BAL cel

113 -0.90]) and the Skin Stigma raw score of the Sarcoidosis Assessment Tool (Pearson product moment corr

114 The Sarcoidosis Assessment Tool (SAT), a sarcoidosis-specifi

115 t these T cells are recognizing the putative sarcoidosis-associated Ag(s) in the context of DR3.

116 hy and diseased control subjects to discover sarcoidosis-associated autoantigens.

117 Four proteins are here proposed as sarcoidosis-associated autoimmune targets and of interes

118 We aimed to characterize a large sarcoidosis-associated pulmonary hypertension (SAPH) coh

119 New and improved diagnostic tests for sarcoidosis-associated uveitis are needed because the cu

120 Although patients with sarcoidosis-associated uveitis had the highest mean (SD)

121 ge, 55+/-10 years) with diagnosis of cardiac sarcoidosis based on Heart Rhythm Society criteria and V

122 percentages among BAL cells of patients with sarcoidosis, beryllium disease, and hypersensitivity pne

123 heral blood and BAL cells from patients with sarcoidosis, beryllium sensitivity, or hypersensitivity

124 and provide suggestions for highly warranted sarcoidosis biomarkers.

125 These data suggest that in sarcoidosis, both pathways, namely IRAK and Rip2, are de

126 ctors affect not only the risk of developing sarcoidosis but also the disease course, which is highly

127 y worsens outcomes in patients with advanced sarcoidosis, but its optimal management is unknown.

128 th worse disease severity at presentation in sarcoidosis, but the relative importance of socioeconomi

129 sy may be increased, especially in suspected sarcoidosis, by the use of electrogram guidance to targe

130 Pulmonary sarcoidosis can be asymptomatic or result in impairment

131 ar tachycardia (VT) in patients with cardiac sarcoidosis can be challenging because of the complex un

132 Nevertheless, the diagnosis of cardiac sarcoidosis can be enhanced by integrating both clinical

133 Cardiac sarcoidosis can occur in patients with established sarco

134 In a two-stage design, 1,726 German sarcoidosis cases and 5,482 control subjects were genoty

135 ve for aquaporin-4-immunoglobulin G, and all sarcoidosis cases were pathologically confirmed.

136 fluid (BALF) proteins in recently diagnosed sarcoidosis cases.

137 Pulmonary involvement occurs in up to 95% of sarcoidosis cases.

138 edominant producer of IFN-gamma in pulmonary sarcoidosis, challenging the Th1 paradigm of pathogenesi

139 idosis in 13 patients treated at a cutaneous sarcoidosis clinic in a 1-day study on October 24, 2014;

140 rting enzyme level in patients with presumed sarcoidosis compared to ankylosing spondylitis (p = 0.00

141 72 proteins were differentially expressed in sarcoidosis compared to controls.

142 s are significant for patients with presumed sarcoidosis compared to ocular involvement of other auto

143 ercentages of Th17.1 cells in lung lavage in sarcoidosis compared with controls in two separate cohor

144 er adverse cardiac outcomes in patients with sarcoidosis compared with matched control subjects.

145 gan involved, combined pulmonary and cardiac sarcoidosis (CS) account for most of the morbidity and m

146 The 3 principal manifestations of cardiac sarcoidosis (CS) are conduction abnormalities, ventricul

147 Background The diagnostic yield of cardiac sarcoidosis (CS) by endomyocardial biopsy is limited.

148 ogy, characteristics, and outcome of cardiac sarcoidosis (CS) in Finland.

149 Cardiac sarcoidosis (CS) may manifest as arrhythmia or even sudd

150 Patients with sarcoidosis demonstrate higher T1, extracellular volume,

151 and nondermatologists in assessing cutaneous sarcoidosis disease activity.

152 nd Severity Index (SASI) to assess cutaneous sarcoidosis disease severity and the Physician's Global

153 his study we evaluated whether veterans with sarcoidosis exhibited different plasma metabolomic and m

154 ion is recommended for patients with cardiac sarcoidosis, giant cell myocarditis, and myocarditis ass

155 In situ hybridization of sarcoidosis granulomatous lung tissues showed abundance

156 severity (healthy control --> uncomplicated sarcoidosis --> complicated sarcoidosis).

157 Patients with sarcoidosis had a higher associated risk of HF and other

158 patients with IgG4-RD, but not patients with sarcoidosis, had increased numbers of circulating plasma

159 Individuals with cardiac sarcoidosis have an increased risk of ventricular arrhyt

160 % to 25% of patients with pulmonary/systemic sarcoidosis have asymptomatic cardiac involvement (clini

161 It is estimated that 5% of patients with sarcoidosis have clinically manifest cardiac involvement

162 h-related quality of life as assessed by the Sarcoidosis Health Questionnaire (P < 0.001), and experi

163 eously achieve full remission (uncomplicated sarcoidosis), however, 20% of sarcoidosis-affected indiv

164 4 rheumatologists evaluated facial cutaneous sarcoidosis in 13 patients treated at a cutaneous sarcoi

165 sorder (NMOSD) in 3%, infectious type in 2%, sarcoidosis in 2%, seronegative NMOSD in 1%, and medicat

166 itis was the initial presenting complaint of sarcoidosis in 78.8% (n = 89).

167 and safety of anti-TNF in treating cutaneous sarcoidosis in a large observational study.

168 on and 29 subsequently developed symptomatic sarcoidosis in an organ uninvolved at uveitis onset.

169 t common pathogenic mechanisms contribute to sarcoidosis in different sites.

170 hat sIL-2R is a useful marker for diagnosing sarcoidosis in patients with uveitis and has slightly be

171 sIL-2R) with ACE as diagnostic biomarkers of sarcoidosis in patients with uveitis.

172 ts for serum sIL-2R and ACE levels to define sarcoidosis in patients with uveitis.

173 rent between progressive and non-progressive sarcoidosis in the BALF included CD28 signaling and PFKF

174 highlights the possibility of recurrence of sarcoidosis in the setting of maintenance immunosuppress

175 e, we analyzed data from 2,318 patients with sarcoidosis in the United States to determine the effect

176 Uveitis was the initial presentation of sarcoidosis in the vast majority of our subjects.

177 In addition, this study suggests that sarcoidosis in veterans may be an occupational disease.

178 naling and previously implicated pathways in sarcoidosis, including phagosome maturation, clathrin-me

179 Peripheral blood monocytes play a role in sarcoidosis inflammation.

180 at activation of p38 plays a pivotal role in sarcoidosis inflammatory response.

181 Gene expression in sarcoidosis involving the orbit or lacrimal gland can be

182 Sarcoidosis is a chronic disease of unknown etiology cha

183 While sarcoidosis is a chronic granulomatous disease presumabl

184 Sarcoidosis is a complex disease with heterogeneous clin

185 Sarcoidosis is a complex systemic granulomatous disease

186 Sarcoidosis is a complex systemic granulomatous disorder

187 Sarcoidosis is a disorder characterized by granulomatous

188 Sarcoidosis is a granulomatous disease that primarily af

189 Sarcoidosis is a granulomatous lung disorder of unknown

190 Sarcoidosis is a major cause of ocular or periocular inf

191 Sarcoidosis is a multisystem disease of unknown cause.

192 Sarcoidosis is a multisystem disorder of unknown cause,

193 Sarcoidosis is a multisystem granulomatous disease of un

194 Sarcoidosis is a multisystemic inflammatory disease of u

195 Sarcoidosis is a presumptive autoimmune disorder charact

196 Sarcoidosis is an inflammatory disease that affects mult

197 Sarcoidosis is an inflammatory disorder of unknown cause

198 Sarcoidosis is an inflammatory granulomatous disorder ch

199 Cardiac sarcoidosis is associated with an increased risk of hear

200 Lung inflammation due to sarcoidosis is characterized by a complex cascade of imm

201 Pulmonary sarcoidosis is classically defined by T-helper (Th) cell

202 The pathogenesis of sarcoidosis is incompletely understood and diagnosis oft

203 s indicate that the inflammatory response in sarcoidosis is induced by specific antigens, possibly in

204 lpha agents (anti-TNF) in treating cutaneous sarcoidosis is lacking.

205 been satisfied; therefore, the diagnosis of sarcoidosis is never fully secure.Methods: Systematic re

206 which would be useful when the diagnosis of sarcoidosis is not definite.

207 Background: The diagnosis of sarcoidosis is not standardized but is based on three ma

208 As the aetiology of sarcoidosis is unknown, no specific treatment and no pat

209 Treatment of patients with sarcoidosis led to reduced percentages of ABC-like cells

210 An in vitro sarcoidosis-like granuloma model was developed by challe

211 8; P = .03), and less than 4 extraneurologic sarcoidosis localizations (OR, 3.06; 95% CI, 1.04-8.98;

212 Further investigation revealed that sarcoidosis macrophages and monocytes exhibit higher pro

213 ed levels of ABC-like cells in patients with sarcoidosis may be useful in diagnosis.

214 Cardiac involvement in sarcoidosis may lead to adverse outcomes such as advance

215 Cardiac sarcoidosis may present with heart failure, left ventric

216 economic outcomes following the diagnosis of sarcoidosis.Measurements and Main Results: In multivaria

217 Hepatic involvement in sarcoidosis might be a perplexing diagnostic problem.

218 tic granulomatous liver disease secondary to sarcoidosis, mimicking a metastatic disease on ultrasono

219 the effects of alpha-MSH in a novel in vitro sarcoidosis model.

220 profile and the cellular pathways altered in sarcoidosis monocytes via RNA-sequencing.

221 ved in phagocytosis and lysosomal pathway in sarcoidosis monocytes, whereas genes involved in proteas

222 oroidopathy (n = 4), idiopathic (n = 4), and sarcoidosis (n = 1).

223 s with uveitis and presumed or biopsy-proven sarcoidosis (N = 113) were included.

224 ilated cardiomyopathy (n=27), myocarditis or sarcoidosis (n=22), occult myocardial infarction (n=13),

225 9%); other granulomatous diseases, including sarcoidosis (occupational burden, 30%); pulmonary alveol

226 elopment of comorbidities after diagnosis of sarcoidosis occurred in 63% of patients and were strong

227 recipient with a remote history of pulmonary sarcoidosis on chronic immunosuppression who developed r

228 t to (1) determine the prevalence of cardiac sarcoidosis or associated myocardial damage, defined by

229 flammation misdiagnosed initially as cardiac sarcoidosis or myocarditis.

230 dosis can occur in patients with established sarcoidosis, or it can be the sole manifestation of the

231 The validity of cutaneous sarcoidosis outcome instruments for use across medical s

232 ss the reliability and validity of cutaneous sarcoidosis outcome instruments for use by dermatologist

233 determine the association between income and sarcoidosis outcomes after controlling for socioeconomic

234 ys and their possible interaction leading to sarcoidosis pathology.

235 c arrest: 0.96% (95% CI: 0.77% to 1.18%) for sarcoidosis patients and 0.45% (95% CI: 0.38% to 0.53%)

236 function: 0.94% (95% CI: 0.75% to 1.16%) for sarcoidosis patients and 0.51% (95% CI: 0.44% to 0.59%)

237 onfidence interval [CI]: 2.83% to 3.57%) for sarcoidosis patients and 1.72% (95% CI: 1.58% to 1.86%)

238 flutter: 3.44% (95% CI: 3.06% to 3.84%) for sarcoidosis patients and 2.66% (95% CI: 2.49% to 2.84%)

239 ality: 10.88% (95% CI: 10.23% to 11.55%) for sarcoidosis patients and 7.43% (95% CI: 7.15% to 7.72%)

240 ture of monocytes from peripheral blood from sarcoidosis patients and healthy controls via RNA-sequen

241 gnificantly higher NPSR1 levels in sera from sarcoidosis patients compared to healthy controls.

242 oRNA-regulated gene signature differentiates sarcoidosis patients from healthy controls in independen

243 52.9% of sarcoidosis patients had monocytes characterised by low

244 The HRCT scans of chronic sarcoidosis patients tended to show more atypical sarcoi

245 The sarcoidosis patients were divided into those with uveiti

246 Sarcoidosis patients with LGE are at significant risk fo

247 In human sarcoidosis patients, mTORC1 activation, macrophage prol

248 lveolar lavage (BAL) cells and leukocytes of sarcoidosis patients.

249 , which accounts for 10% to 20% of pulmonary sarcoidosis patients.

250 nd elevated blood lysozyme and ACE levels in sarcoidosis patients.

251 idosis patients tended to show more atypical sarcoidosis patterns.

252 creased both IL-1beta and IL-6 production in sarcoidosis PBMCs and moderately in AMs.

253 deling on LS and non-LS indicates that these sarcoidosis phenotypes have different genetic susceptibi

254 sions: These results suggest the burden from sarcoidosis preferentially impacts the economically disa

255 sing spondylitis, behcet's disease, presumed sarcoidosis, presumed latent tuberculosis, presumed late

256 whole blood and monocytes from patients with sarcoidosis produced more TNF and IL-6 compared with hea

257 cular uveitis characteristic and extraocular sarcoidosis progression.

258 There does not appear to be any impact of sarcoidosis recurrence on 1-, 3-, or 5-year survivals.

259 tients had significantly higher rates of new sarcoidosis-related comorbidities (<$35,000, odds ratio

260 functional assays to study CD4(+) T cells in sarcoidosis revealed a marked expansion of Th17.1 cells

261 fferentially expressed across a continuum of sarcoidosis severity (healthy control --> uncomplicated

262 The myocardium of patients with cardiac sarcoidosis showed many FR-beta-positive macrophages in

263 investigated in another respiratory disease, sarcoidosis, showing significantly higher NPSR1 levels i

264 Our results revealed that the veterans with sarcoidosis significantly differed from civilians, accor

265 The Sarcoidosis Assessment Tool (SAT), a sarcoidosis-specific PRO, was administered in a lung and

266 urements to validate it as a useful clinical sarcoidosis-specific PRO.

267 d the expression of FR-beta in human cardiac sarcoidosis specimens.

268 The majority of individuals with sarcoidosis spontaneously achieve full remission (uncomp

269 from 20 healthy volunteers, 26 patients with sarcoidosis stage III and IV, and 29 patients with chron

270 ctivity in 73 BAL samples from subjects with sarcoidosis, subjects with asthma, and healthy subjects.

271 Non-inflammatory effects of sarcoidosis, such as pulmonary hypertension and bronchie

272 t three cases with a longstanding history of sarcoidosis that have been additionally diagnosed with c

273 yndrome (LS) is a characteristic subgroup of sarcoidosis that is associated with a good prognosis in

274 n sarcoidosis and known or suspected cardiac sarcoidosis that underwent cardiovascular magnetic reson

275 ranulomatosis, a variant form of "classical" sarcoidosis, that became clinically apparent in the form

276 In sarcoidosis, the proinflammatory cytokines interferon ga

277 STAT (Sarcoidosis Treated with Anti-TNF) is a French retrospec

278 fic PRO, was administered in a lung and skin sarcoidosis treatment trial.

279 diseases such as lymphocytic myocarditis and sarcoidosis) using the gold-standard Dallas criteria.

280 e to the development of symptomatic systemic sarcoidosis was 12 months.

281 rtality for all patients with a diagnosis of sarcoidosis was 2.0%.

282 of computed tomography (CT), the severity of sarcoidosis was assessed based on chest X-ray abnormalit

283 Concurrent undiagnosed systemic sarcoidosis was common at the time of uveitis onset.

284 Systemic sarcoidosis was identified in 10.7%, and was biopsy prov

285 Recurrence of sarcoidosis was noted among 7 patients (pathological rec

286 Systemic sarcoidosis was present in 39% of patients.

287 Among subsequent diagnoses, sarcoidosis was the most common (19/52 or 36.5%), follow

288 vitamin D-binding protein as a biomarker for sarcoidosis, we investigated plasma exosomes from 23 pat

289 Subjects with a diagnosis of sarcoidosis were less likely to require a second-line ag

290 autopsy samples from 6 patients with cardiac sarcoidosis were studied for macrophages and FR-beta.

291 red as inflammatory markers for diagnosis of sarcoidosis which is an autoimmune inflammatory disease.

292 exclusively in those with fibrotic pulmonary sarcoidosis, which accounts for 10% to 20% of pulmonary

293 ular ejection fraction >50% and extracardiac sarcoidosis who underwent cardiovascular magnetic resona

294 rols and Caucasian non-smoking patients with sarcoidosis who were not taking disease modifying therap

295 About half of patients with sarcoidosis will need systemic therapy for their disease

296 tentially lifesaving for some illnesses (eg, sarcoidosis with cardiac involvement) and is critical to

297 ings reveal a substantial genetic overlap of sarcoidosis with diverse immune-mediated inflammatory di

298 from patients with confirmed treatment-naive sarcoidosis with microparticles generated from Mycobacte

299 l was significant for patients with presumed sarcoidosis with respect to ankylosing spondylitis (p =

300 ed for cohort studies of patients with known sarcoidosis with suspected cardiac involvement who under